EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
- Mechanism
- Curator reviewed
EGEN-001 inhibits cancer growth by stimulating the immune system and is the first clinical use of a non-viral IL-12 gene therapy approach for treating ovarian cancer. The product, formulated using the company's proprietary TheraPlas(TM) technology, is composed of interleukin-12 gene expression plasmid and a biocompatible delivery polymer. EGEN-001 is designed to increase the local concentration of interleukin-12, a potent anti-cancer cytokine. Unlike standard chemotherapeutic agents, the IL-12 cytokine is known for its ability to inhibit cancer growth by stimulating the immune system.
- Primary indication
- Investigated for use/treatment in gene therapy and ovarian cancer.Curator reviewed
- Code names
- EGEN-001 · GEN-1 · IMNN-001
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with EGEN-001, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account